Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Top Cited Papers
- 1 February 2010
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 11 (2) , 155-164
- https://doi.org/10.1016/s1470-2045(09)70334-1
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 2009
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV MelanomaClinical Cancer Research, 2009
- Phase I/II Study of Ipilimumab for Patients With Metastatic MelanomaJournal of Clinical Oncology, 2008
- Anti–Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer TreatmentJournal of Clinical Oncology, 2008
- Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 BlockadeClinical Cancer Research, 2007
- Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4)Cancer, 2007
- Principles and use of anti-CTLA4 antibody in human cancer immunotherapyCurrent Opinion in Immunology, 2006
- Cutaneous melanoma: available therapy for metastatic diseaseDermatologic Therapy, 2006
- Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II StudyAnnals of Surgical Oncology, 2005
- Enhancement of Antitumor Immunity by CTLA-4 BlockadeScience, 1996